Lydia Scarfò

6.7k total citations · 1 hit paper
111 papers, 2.3k citations indexed

About

Lydia Scarfò is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Lydia Scarfò has authored 111 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 95 papers in Genetics, 49 papers in Pathology and Forensic Medicine and 41 papers in Immunology. Recurrent topics in Lydia Scarfò's work include Chronic Lymphocytic Leukemia Research (94 papers), Lymphoma Diagnosis and Treatment (49 papers) and Immunodeficiency and Autoimmune Disorders (24 papers). Lydia Scarfò is often cited by papers focused on Chronic Lymphocytic Leukemia Research (94 papers), Lymphoma Diagnosis and Treatment (49 papers) and Immunodeficiency and Autoimmune Disorders (24 papers). Lydia Scarfò collaborates with scholars based in Italy, Greece and United States. Lydia Scarfò's co-authors include Paolo Ghia, Andrés J.M. Ferreri, Federico Caligaris‐Cappio, Cristina Scielzo, Claudia Fazi, Marta Muzio, Maria Teresa Sabrina Bertilaccio, Antonis Dagklis, Κώστας Σταματόπουλος and Benedetta Apollonio and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.

In The Last Decade

Lydia Scarfò

103 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients

2020 330 citations Lydia Scarfò, Thomas Chatzikonstantinou et al. Blood profile →

Peers

Countries citing papers authored by Lydia Scarfò

Since Specialization

Citations

This map shows the geographic impact of Lydia Scarfò's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lydia Scarfò with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lydia Scarfò more than expected).

Fields of papers citing papers by Lydia Scarfò

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lydia Scarfò. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lydia Scarfò. The network helps show where Lydia Scarfò may publish in the future.

Co-authorship network of co-authors of Lydia Scarfò

This figure shows the co-authorship network connecting the top 25 collaborators of Lydia Scarfò. A scholar is included among the top collaborators of Lydia Scarfò based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lydia Scarfò. Lydia Scarfò is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Bcor loss promotes Richter transformation of chronic lymphocytic leukemia associated with Notch1 activation in mice 2025 ·Leukemia ·(unknown), Francesco Maria Adamo, Daniele Sorcini, Filomena De Falco, (unknown), Giovanni Martino, Barbara Bigerna, (unknown), (unknown), Angela Espósito, (unknown), (unknown), Jessica Bordini, Lydia Scarfò, Emanuela Rosati, Paolo Ghia, Brunangelo Falini, Paolo Sportoletti	2
2	Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice 2025 ·Leukemia ·Piers Blombery, Thomas Chatzikonstantinou, (unknown), Richard Rosenquist, Gianluca Gaïdano, Šárka Pospı́šilová, Andrew W. Roberts, Richard W. Birkinshaw, Davide Rossi, Lydia Scarfò, John F. Seymour, Stephan Stilgenbauer, Adrian Wiestner, Jennifer A. Woyach, (unknown), Paolo Ghia, Κώστας Σταματόπουλος	0
3	Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study 2024 ·Blood ·Meghan C. Thompson, Ricardo Parrondo, Anna Maria Frustaci, John N. Allan, Paolo Ghia, Irina Mocanu, Constantine S. Tam, Judith Trotman, Inhye E. Ahn, Stephan Stilgenbauer, Lydia Scarfò, Xiangmei Chen, Kunthel By, (unknown), Daniel O. Persky, Amit Agarwal, John F. Seymour	14
4	Disrupting pro-survival and inflammatory pathways with dimethyl fumarate sensitizes chronic lymphocytic leukemia to cell death 2024 ·Cell Death and Disease ·(unknown), (unknown), (unknown), Jessica Bordini, (unknown), Michela Riba, Pamela Ranghetti, (unknown), Paolo Ghia, Lydia Scarfò, Marta Muzio	8
5	Realizing precision medicine in chronic lymphocytic leukemia: Remaining challenges and potential opportunities 2024 ·HemaSphere ·Κώστας Σταματόπουλος, Šárka Pavlová, Othman Al‐Sawaf, Thomas Chatzikonstantinou, Christina Karamanidou, Gianluca Gaïdano, Florence Cymbalista, Arnon P. Kater, Andy C. Rawstron, Lydia Scarfò, Paolo Ghia, Richard Rosenquist	2
6	Dimethyl itaconate selectively targets inflammatory and metabolic pathways in chronic lymphocytic leukemia 2023 ·European Journal of Immunology ·(unknown), (unknown), (unknown), Michela Riba, Pamela Ranghetti, Lydia Scarfò, Paolo Ghia, Marta Muzio	6
7	Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study 2023 ·Blood Advances ·Carol Moreno, (unknown), Constantine S. Tam, Andrew Grigg, Lydia Scarfò, Thomas J. Kipps, (unknown), Raghuveer Singh Mali, Cathy Zhou, James P. Dean, Edith Szafer‐Glusman, Michael Y. Choi	10
8	Real‐world evidence on venetoclax in chronic lymphocytic leukemia: The Italian experience 2023 ·Hematological Oncology ·Luca Laurenti, Lydia Scarfò, Anna Maria Frustaci, Alessandro Sanna, (unknown), Morena Caira, (unknown), (unknown), Benedetta Neri, Stefano Molica, Francesca Romana Mauro	4
9	MyPal-Child study protocol: an observational prospective clinical feasibility study of the MyPal ePRO-based early palliative care digital system in paediatric oncology patients 2021 ·BMJ Open ·(unknown), Christina Karamanidou, Sheila Payne, (unknown), Annette Sander, Julia Downing, Κώστας Σταματόπουλος, Julie Ling, Cathy Payne, Lydia Scarfò, (unknown), (unknown), Norbert Graf	10
10	MyPal ADULT study protocol: a randomised clinical trial of the MyPal ePRO-based early palliative care system in adult patients with haematological malignancies 2021 ·BMJ Open ·Lydia Scarfò, Christina Karamanidou, Michael Doubek, (unknown), (unknown), Charalampos Pontikoglou, Julie Ling, Cathy Payne, Helen Α. Papadaki, Richard Rosenquist, Niki Stavroyianni, Sheila Payne, Paolo Ghia, Pantelis Natsiavas, (unknown), Κώστας Σταματόπουλος	10
11	Exploiting B-cell Receptor Stereotypy to Design Tailored Immunotherapy in Chronic Lymphocytic Leukemia 2020 ·Clinical Cancer Research ·(unknown), Cristina Maccalli, Lydia Scarfò, Paolo Dellabona, Κώστας Σταματόπουλος, Paolo Ghia	6
12	Interleukin‐1 receptor‐associated kinase 4 inhibitor interrupts toll‐like receptor signalling and sensitizes chronic lymphocytic leukaemia cells to apoptosis 2020 ·British Journal of Haematology ·(unknown), (unknown), (unknown), (unknown), Pamela Ranghetti, (unknown), Piera Angelillo, Lydia Scarfò, Paolo Ghia, Marta Muzio	10
13	BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia 2020 ·Frontiers in Immunology ·Stefania Fiorcari, Rossana Maffei, Daniela Vallerini, Lydia Scarfò, Patrizia Barozzi, Monica Maccaferri, Leonardo Potenza, Paolo Ghia, Mario Luppi, Roberto Marasca	38
14	Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia 2019 ·Cancer Immunology Research ·(unknown), Ronghua Zhang, Cristina Ivan, Giovanni Galletti, Karen Clise-Dwyer, Federica Barbaglio, Lydia Scarfò, Miguel Aracil, Christian Klein, William G. Wierda, William Plunkett, Federico Caligaris‐Cappio, Varsha Gandhi, Michael J. Keating, Maria Teresa Sabrina Bertilaccio	38
15	Monoclonal B-cell lymphocytosis: Does the elderly patient need a specialistic approach? 2018 ·European Journal of Internal Medicine ·Piera Angelillo, Antonella Capasso, Paolo Ghia, Lydia Scarfò	4
16	Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis 2017 ·Blood ·Francesca Gorini, Laura Azzimonti, Gloria Delfanti, Lydia Scarfò, Cristina Scielzo, Maria Teresa Sabrina Bertilaccio, Pamela Ranghetti, Alessandro Gulino, Claudio Doglioni, Arianna Di Napoli, Miriam Capri, Claudio Franceschi, Federico Caligaris‐Cappio, Paolo Ghia, Matteo Bellone, Paolo Dellabona, Giulia Casorati, Claudia de Lalla	63
17	High throughput immunoprofiling of chronic lymphocytic leukemia patients assigned to stereotyped subset #4 : novel insights into the depth, diversity and temporal dynamics of clonal evolution 2017 ·Leukemia & lymphoma ·Lesley Ann Sutton, Diego Cortese, Viktor Ljungström, Karla Plevová, Davide Rossi, Evangelia Stalika, Andreas Agathangelidis, Lydia Scarfò, (unknown), Anton W. Langerak, Šárka Pospı́šilová, Frédéric Davi, Paolo Ghia, Κώστας Σταματόπουλος, (unknown)	1
18	Ex Vivo Lymph Node Native Microenvironment Assay Shows Novel Antiproliferative Activity For Idelalisib And Ibrutinib On Cll Cells 2016 ·Haematologica ·(unknown), Lydia Scarfò, Mattias Mattsson, Aliki Xochelli, Pamela Ranghetti, (unknown), (unknown), (unknown), Joaquín Martínez‐López, Javier de la Serna, (unknown), Veerendra Munugalavadla, Stacey Tannheimer, Richard Rosenquist, Κώστας Σταματόπουλος, Paolo Ghia	1
19	INTERIM RESULTS FROM A PHASE IIA STUDY OF THE ANTI-CXCL12 SPIEGELMER OLAPTESED PEGOL (NOX-A12) IN COMBINATION WITH BENDAMUSTINE/RITUXIMAB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA 2014 ·Haematologica ·Michael Steurer, Lydia Scarfò, Marco Montillo, Ann Janssens, Sophie Wildner, Francesca Romana Mauro, Livio Trentin, J. Thaler, Sonja Burgstaller, Anna Kruschinski, (unknown), (unknown), Paolo Ghia, Federico Caligaris‐Cappio, Marco Gobbi	2
20	In Vitro Sensitivity of CLL Cells to Fludarabine May Be Modulated by the Stimulation of Toll-like Receptors 2012 ·Clinical Cancer Research ·(unknown), Benedetta Apollonio, Lydia Scarfò, Pamela Ranghetti, Claudia Fazi, Paolo Ghia, Federico Caligaris‐Cappio, Marta Muzio	37

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact